McKesson is expected to report Q2 2026 revenue of $104.25 billion and adjusted EPS of $9.44, with the current stock price of $850.02 trading below the average analyst target of $941.47. Investors are primarily focused on the impact of surging GLP-1 weight-loss drug script demand on the Prescription Technology Solutions (RxTS) segment's profit margins.
While high pharmaceutical distribution volumes are driving top-line growth, the shift toward cash-pay dynamics has raised concerns about margin compression in high-margin technology services. Management's updated full-year fiscal 2027 guidance and progress in the oncology and specialty platforms will be critical for sustaining the stock's recent momentum.